{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:17:18Z","timestamp":1791307038318,"version":"4.3.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1124\/jpet.104.075382","type":"journal-article","created":{"date-parts":[[2005,4,14]],"date-time":"2005-04-14T00:35:17Z","timestamp":1113438917000},"page":"862-869","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["WAY-163909 [(7 bR, 10 aR)-1,2,3,4,8,9,10,10 a-Octahydro-7 bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Anorectic Activity"],"prefix":"10.1016","volume":"313","author":[{"given":"John","family":"Dunlop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annmarie L.","family":"Sabb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Mazandarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Kalgaonker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Shukhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Sukoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Stack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyd L.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Rosenzweig-Lipson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.104.075382_bib1","doi-asserted-by":"crossref","unstructured":"Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, and Weiden PJ (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156: 1686\u20131696.","DOI":"10.1176\/ajp.156.11.1686"},{"key":"10.1124\/jpet.104.075382_bib2","doi-asserted-by":"crossref","unstructured":"Barnes NM and Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38: 1083\u20131152.","DOI":"10.1016\/S0028-3908(99)00010-6"},{"key":"10.1124\/jpet.104.075382_bib3","doi-asserted-by":"crossref","unstructured":"Baxter G, Kennett G, Blaney F, and Blackburn T (1995) 5-HT2 receptor subtypes: a family re-united? Trends Pharmacol Sci 16: 105\u2013110.","DOI":"10.1016\/S0165-6147(00)88991-9"},{"key":"10.1124\/jpet.104.075382_bib4","doi-asserted-by":"crossref","unstructured":"Berendsen HH (1995) Interactions between 5-hydroxytryptamine receptor subtypes. Pharmacol Ther 66: 17\u201337.","DOI":"10.1016\/0163-7258(94)00075-E"},{"key":"10.1124\/jpet.104.075382_bib5","doi-asserted-by":"crossref","unstructured":"Bickerdike MJ (2003) 5-HT2C receptor agonists as potential drugs for the treatment of obesity. Curr Top Med Chem 3: 885\u2013897.","DOI":"10.2174\/1568026033452249"},{"key":"10.1124\/jpet.104.075382_bib6","doi-asserted-by":"crossref","unstructured":"Bos M, Jenck F, Martin JR, Moreau JL, Sleight AJ, Wichmann J, and Widmer U (1997) Novel agonists of 5-HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder. J Med Chem 40: 2762\u20132769.","DOI":"10.1021\/jm970030l"},{"key":"10.1124\/jpet.104.075382_bib7","doi-asserted-by":"crossref","unstructured":"Cowen PJ, Sargent PA, Williams C, Goodall EM, and Orlikov AB (1995) Hypophagic, endocrine and subjective responses to m-chlorophenylpiperzine in healthy men and women. Hum Psychopharmacology 10: 385\u2013391.","DOI":"10.1002\/hup.470100504"},{"key":"10.1124\/jpet.104.075382_bib8","doi-asserted-by":"crossref","unstructured":"Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, et al. (2000) Possible role of valvular 5-HT2b receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57: 75\u201381.","DOI":"10.1016\/S0026-895X(24)26444-0"},{"key":"10.1124\/jpet.104.075382_bib9","doi-asserted-by":"crossref","unstructured":"Fozard RJR and Gray JA (1989) 5-HT1C receptor activation: a key step in the initiation of migraine? Trends Pharmacol Sci 10: 307\u2013309.","DOI":"10.1016\/0165-6147(89)90061-8"},{"key":"10.1124\/jpet.104.075382_bib10","doi-asserted-by":"crossref","unstructured":"Gibson EL, Barnfield AM, and Curzon G (1994) Evidence that mCPP-induced anxiety in the plus maze is mediated by postsynaptic 5-HTsC receptors but not by sympathomimetic effects. Neuropharmacology 33: 457\u2013465.","DOI":"10.1016\/0028-3908(94)90076-0"},{"key":"10.1124\/jpet.104.075382_bib11","doi-asserted-by":"crossref","unstructured":"Hayashi A, Sonoda R, Kimura Y, Takasu T, Suzuki M, Sasamata M, and Miyata K (2004) Antiobesity effect of YM348, a novel 5-HT2C receptor agonist in Zucker rats. Brain Res 1011: 221\u2013227.","DOI":"10.1016\/j.brainres.2004.03.032"},{"key":"10.1124\/jpet.104.075382_bib12","doi-asserted-by":"crossref","unstructured":"Heisler LK, Chu HM, and Tecott LH (1998) Epilepsy and obesity in serotonin 5-HT2C receptor mutant mice. Ann NY Acad Sci 861: 74\u201378.","DOI":"10.1111\/j.1749-6632.1998.tb10175.x"},{"key":"10.1124\/jpet.104.075382_bib13","doi-asserted-by":"crossref","unstructured":"Kennett GA and Curzon G (1988) Evidence that hypophagia induced by mCPP and TFMPPrequires 5-HT1C and 5-HT1B receptors; hypophagia induced by RU 24969 requires only 5-HT1B receptors. Psychopharmacology 96: 93\u2013100.","DOI":"10.1007\/BF02431539"},{"key":"10.1124\/jpet.104.075382_bib14","doi-asserted-by":"crossref","unstructured":"Kennett GA and Curzon G (1991) Potencies of 5-HT1C antagonists indicate that receptors mediated mCPP-induced hypophagia. Br J Pharmacol 103: 2016\u20132020.","DOI":"10.1111\/j.1476-5381.1991.tb12369.x"},{"key":"10.1124\/jpet.104.075382_bib15","doi-asserted-by":"crossref","unstructured":"Kennett GA, Trail B, and Bright F (1998) Anxiolytic-like actions of BW 723C86 in the rat Vogel conflict test are 5-HT2B mediated. Neuropharmacology 37: 1603\u20131610.","DOI":"10.1016\/S0028-3908(98)00115-4"},{"key":"10.1124\/jpet.104.075382_bib16","doi-asserted-by":"crossref","unstructured":"Kennett GA, Wood, MD, Bright F, Trail B, Riley G, Holland V, Avenell KY, Stean T, Upton N, Bromidge S, et al. (1997) SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 36: 609\u2013620.","DOI":"10.1016\/S0028-3908(97)00038-5"},{"key":"10.1124\/jpet.104.075382_bib17","doi-asserted-by":"crossref","unstructured":"Kimura Y, Hatanaka K, Naitou Y, Maeno K, Shimada I, Koakutsu A, Wanibuchi F, and Yamaguchi T (2004) Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist. Eur J Pharmacol 283: 37\u201343.","DOI":"10.1016\/j.ejphar.2003.10.004"},{"key":"10.1124\/jpet.104.075382_bib18","doi-asserted-by":"crossref","unstructured":"Launay JM, Herve P, Peoc\u2019h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, et al. (2002) Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 8: 1129\u20131135.","DOI":"10.1038\/nm764"},{"key":"10.1124\/jpet.104.075382_bib19","doi-asserted-by":"crossref","unstructured":"Leyson D and Kelder J (1998) Ligands for the 5-HT2C receptor as potential antidepressants and anxiolytics, in Trends in Drug Research (van der Groot J ed) pp 49\u201361, Elsevier, Amsterdam.","DOI":"10.1016\/S0165-7208(98)80044-5"},{"key":"10.1124\/jpet.104.075382_bib20","doi-asserted-by":"crossref","unstructured":"Martin JR, Bos M, Jenck F, Moreau J-L, Mutel V, Sleight AJ, Wichmann J, Andrews JS, Berendsen HHG, Broekkamp CLE, et al. (1998) 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286: 913\u2013924.","DOI":"10.1016\/S0022-3565(24)37669-4"},{"key":"10.1124\/jpet.104.075382_bib21","doi-asserted-by":"crossref","unstructured":"Masand PS (2000) Weight gain associated with psychotropic drugs. Expert Opin Pharmacother 1: 377\u2013389.","DOI":"10.1517\/14656566.1.3.377"},{"key":"10.1124\/jpet.104.075382_bib22","unstructured":"McCall RB, Franklin SR, Hyslop DK, Knauer CS, Chio CL, Haber CL, and Fitzgerald LW (2001) PNU-22394, a 5-HT2C receptor agonist, reduces feeding in rodents and produces weight loss in humans. Soc Neurosci Abstr 27: 309.2."},{"key":"10.1124\/jpet.104.075382_bib23","doi-asserted-by":"crossref","unstructured":"Millan MJ, Peglion JL, Lavielle G, and Perrin-Monneyron S (1997) 5-HT2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists. Eur J Pharmacol 325: 9\u201312.","DOI":"10.1016\/S0014-2999(97)89962-1"},{"key":"10.1124\/jpet.104.075382_bib24","doi-asserted-by":"crossref","unstructured":"Nonogaki K, Strack AM, Dallman MF, and Tecott LH (1998) Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Med 4: 1152\u20131156.","DOI":"10.1038\/2647"},{"key":"10.1124\/jpet.104.075382_bib25","unstructured":"Rosenzweig-Lipson S, Coupet J, Dunlop J, and McGonigle P (2000) Antiobesity-like effects of the selective 5-HT2C agonist WAY-161503. FASEB J 14: A1321."},{"key":"10.1124\/jpet.104.075382_bib26","doi-asserted-by":"crossref","unstructured":"Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, and Roth BL (2000) Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102: 2836\u20132841.","DOI":"10.1161\/01.CIR.102.23.2836"},{"key":"10.1124\/jpet.104.075382_bib27","doi-asserted-by":"crossref","unstructured":"Sabb AL, Vogel RL, Welmaker G, Sabalski JE, Coupet J, Dunlop J, Rosenzweig-Lipson S, and Harrison B (2004) Cycyloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT2C receptor. Bioorg Med Chem Lett 14: 2603\u20132607.","DOI":"10.1016\/j.bmcl.2004.02.100"},{"key":"10.1124\/jpet.104.075382_bib28","doi-asserted-by":"crossref","unstructured":"Samanin R, Mennini T, Ferraris A, Bendotti C, Borsini F, and Garattini S (1979) m-Chlorophenylpiperazine: a central serotonin agonist causing powerful anorexia in rats. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 308: 159\u2013163.","DOI":"10.1007\/BF00499059"},{"key":"10.1124\/jpet.104.075382_bib29","doi-asserted-by":"crossref","unstructured":"Sanders-Bush E and Breeding M (1991) Choroid plexus epithelial cells in primary culture: a model of 5-HT1C receptor activation by hallucinogenic drugs. Psychopharmacology 105: 340\u2013346.","DOI":"10.1007\/BF02244428"},{"key":"10.1124\/jpet.104.075382_bib30","doi-asserted-by":"crossref","unstructured":"Sargent PA, Sharpley AL, Williams C, Goodall EM, and Cowen PJ (1997) 5-HT2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology 133: 209\u2013312.","DOI":"10.1007\/s002130050407"},{"key":"10.1124\/jpet.104.075382_bib31","doi-asserted-by":"crossref","unstructured":"Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, and Julius D (1995) Eating disorder and epilepsy in mice lacking 5-HT2C receptors. Nature (Lond) 374: 542\u2013546.","DOI":"10.1038\/374542a0"},{"key":"10.1124\/jpet.104.075382_bib32","doi-asserted-by":"crossref","unstructured":"Vickers SP, Benwell KR, Porter RH, Bickerdike MJ, Kennett GA, and Dourish CT (2000) Comparative effects of continuous infusion of mCPP, Ro 60-0175 and d-fenfluramine on food intake, water intake, body weight and locomotor activity in rats. Br J Pharmacol 130: 1305\u20131314.","DOI":"10.1038\/sj.bjp.0703443"},{"key":"10.1124\/jpet.104.075382_bib33","doi-asserted-by":"crossref","unstructured":"Vickers SP, Easton N, Webster LJ, Wyatt A, Bickerdike MJ, Dourish CT, and Kennett GA (2003) Oral administration of the 5-HT2C receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia. Psychopharmacology 167: 274\u2013280.","DOI":"10.1007\/s00213-002-1378-6"},{"key":"10.1124\/jpet.104.075382_bib34","doi-asserted-by":"crossref","unstructured":"Walsh AE, Smith KA, Oldman AD, Williams C, Goodall EM, and Cowen PJ (1994) m-Chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacology 116: 120\u2013122.","DOI":"10.1007\/BF02244883"},{"key":"10.1124\/jpet.104.075382_bib35","doi-asserted-by":"crossref","unstructured":"Welmaker GS, Nelson JA, Sabalski JE, Sabb AL, Potoski JR, Graziano D, Kagan K, Coupet J, Dunlop J, Mazandarani H, et al. (2000) Synthesis and 5-hydroxytryptamine (5-HT) activity of 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5-(6H) ones and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxalines. Bioorg Med Chem Lett 10: 1991\u20131994.","DOI":"10.1016\/S0960-894X(00)00400-5"},{"key":"10.1124\/jpet.104.075382_bib36","unstructured":"Whitaker R (2000) Atypical antipsychotics: a modest advance in treating schizophrenia. Spectrum. Life Sci Decision Resource 2: 1\u20139."}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524319822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524319822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.104.075382","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T21:23:22Z","timestamp":1740000202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524319822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S0022356524319822"],"URL":"https:\/\/doi.org\/10.1124\/jpet.104.075382","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"WAY-163909 [(7 bR, 10 aR)-1,2,3,4,8,9,10,10 a-Octahydro-7 bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Anorectic Activity","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.104.075382","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2005 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}